| (210) | Number of the EPO application | 17823017 |
| (220) | Filing date of the EPO application | 2017.09.29 |
| (80) | EPO patent specification publication (B) | EPB nr. 46/2024, 2024.11.13 |
| (110) | EPO patent number | 3518932 |
| (21) | Number of the application | e 2019 0879 |
| (71) | Name(s) of applicant(s), code of the country | Sumitomo Pharma Switzerland GmbH, CH;
Takeda Pharmaceutical Company Limited, JP; |
| (72) | Name(s) of inventor(s), code of the country | RAJASEKHAR Vijaykumar Reddy, US;
JOHNSON Brendan Mark, US;
MACLEAN David B., US;
SEELY Lynn, US;
MUDD Paul N., US;
FAESSEL Hélène M., US; |
| (73) | Name(s) of owner(s), code of the country | Sumitomo Pharma Switzerland GmbH, CH;
TAKEDA Pharmaceutical Company Limited, JP; |
| (54) | Title of the invention | TREATMENT OF PROSTATE CANCER |
| (13) | Kind-of-document code | A1 |
| (51) | International Patent Classification | A61K 31/513 (2006.01.01); A61P 35/00 (2006.01.01) |
| (19) | Country | CH |
| (41) | Date of publication of the application | 2019.09.30 |
| (30) | Priority | 201662402150 P, 2016.09.30, US; 201662402004 P, 2016.09.30, US |
| (86) | International application | PCT/EP2017/074849, 2017.09.29 |
| (87) | International publication | WO 2018/060463, 2018.04.05 |